Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance
Background Despite advances in early detection and therapies, cancer is still one of the
most common causes of death worldwide. Since each tumor is unique, there is a need to …
most common causes of death worldwide. Since each tumor is unique, there is a need to …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies
BACKGROUND Liquid biopsies that are based on analysis of cell-free DNA from plasma
offer diagnostic information that is otherwise accessible conventionally through invasive …
offer diagnostic information that is otherwise accessible conventionally through invasive …
Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
Tumor microenvironment complexity and therapeutic implications at a glance
R Baghban, L Roshangar… - Cell Communication and …, 2020 - Springer
The dynamic interactions of cancer cells with their microenvironment consisting of stromal
cells (cellular part) and extracellular matrix (ECM) components (non-cellular) is essential to …
cells (cellular part) and extracellular matrix (ECM) components (non-cellular) is essential to …
[HTML][HTML] Non-invasive early detection of cancer four years before conventional diagnosis using a blood test
X Chen, J Gole, A Gore, Q He, M Lu, J Min… - Nature …, 2020 - nature.com
Early detection has the potential to reduce cancer mortality, but an effective screening test
must demonstrate asymptomatic cancer detection years before conventional diagnosis in a …
must demonstrate asymptomatic cancer detection years before conventional diagnosis in a …
Liquid biopsy epigenomic profiling for cancer subtyping
SC Baca, JH Seo, MP Davidsohn, B Fortunato… - Nature medicine, 2023 - nature.com
Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical
decisions in cancer care, they have limited ability to identify the transcriptional programs that …
decisions in cancer care, they have limited ability to identify the transcriptional programs that …
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genotyping and longitudinal disease monitoring. However, owing to past emphasis on …
genotyping and longitudinal disease monitoring. However, owing to past emphasis on …
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …